Fully mobilizing host defense: Building better vaccines

Nature Biotechnology

Volumn 16, Issue 11, 1998, Pages 1025-1033

  Raychaudhuri, Syamal ^a   Rock, Kenneth L ^b  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Adjuvant; Cyctotoxic T lymphocytes; Immunization; Microsphere

Indexed keywords

ADJUVANT; CHAPERONE; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ISCOM; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MICROSPHERE; POLYGLACTIN; QS 21; QUIL A; VACCINE;

ANTIGEN PRESENTING CELL; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; HELPER CELL; HOST RESISTANCE; IMMUNIZATION; IMMUNOSTIMULATION; PRIORITY JOURNAL; REVIEW; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS; B-LYMPHOCYTES; BACTERIAL VACCINES; BIOTECHNOLOGY; DENDRITIC CELLS; DRUG DELIVERY SYSTEMS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MACROPHAGES; MICROSPHERES; T-LYMPHOCYTES, CYTOTOXIC; VACCINES; VACCINES, DNA; VIRAL VACCINES;

EID: 0031737698     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/3469     Document Type: Review

References (112)

1. Vincent, T.D., Hellman, S., and Rosenberg S.S. (eds.). Biologic therapy of cancer. J.B. Lippincott Company, Philadelphia, PA.
2. Bloom, B. and Zinkernagel, R. 1996. Immunity to infection. Curr. Opin. Immunol. 8:465-466.
3. Woodrow, G.C. 1997. An overview of biotechnology as applied to vaccine development, pp. 25-34, in New generation vaccines; second edition. Levine, M.M., Woodrow, G.C., Kaper, J.B., and Cobon, G.S. (eds.). Marcel Dekker, New York.
4. Boon, T. and Old, L.J. 1997. Cancertumor antigens. Curr. Opin. Immunol. 9:681-683.
5. Rosenberg, S.A. 1995. The development of new cancer therapies based on the molecular identification of cancer regression antigens. Cancer J. Sci. Am. 1:90.
6. Hunter, R.L., Olsen, M.R., and Bennett, B. 1995. Copolymer adjuvants and titermax, pp. 51-94, in The theory and practical application of adjuvants. Stewart-Tull, D.E.S. (ed.). John Wiley and Sons, Chichester, England.
7. Allsopp, C.E., Plebanski, M., Gilbert, S., Sinden, R.E., Harris, S., Frankel, G. et al. 1996. Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. Eur. J. Immunol. 8:1951-1959.
8. Reynolds, H.Y. 1988. Immunoglobin G and its function in the human respiratory tract. Mayo. Clin. Proc. 63:161-174.
9. Schwartz, J.S. 1982. Pneumococcal vaccine: clinical efficacy and effectiveness. Ann. Intern. Med. 96:208-220.
10. Teng, N.N.H., Kaplan, H.S., Herbert, J.M., Moore, C., Douglas, H., Wunderlich, A. et al. 1985. Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proc. Natl. Acad. Sci. USA 82:1790-1794.
11. Constant, S.L. and Bottomly, K. 1997. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu. Rev. Immunol. 15:297-322.
12. Lerner, R.A., Ginsberg, H.S., Chanock, R.M., and Brown, F. (eds.).Vaccines 89: modern approaches to new vaccines including prevention of AIDS. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
13. Engers, H.D., Lahaye, T., Sorenson, G.D., Sorenson, G.D., Glasebrook, A.L., Horvath, C. et al. 1984. Functional activity In vivo of effector T cell populations. J. Immunol. 133:1664-1670.
14. McMichael, A.J., Gotch, P.M., Nobel, G.R., and Beare, P.A. 1980. Cytotoxic T-cell immunity to influenza. N. Engl. J. Med. 309:13-17.
15. Yee, C., Riddell, S.R., and Greenberg, P.D. 1997. Prospects for, adoptive T cell therapy. Curr. Opin. Immunol. 9:705-708.
16. Rock, K.L. 1996. A new foreign policy: MHC class I molecules monitor the outside world. Immunol. Today 17:131-138.
17. Jondal, M., Schirmbeck, R., and Reimann, J. 1996. MHC Class I-restricted CTL responses to exogenous antigens. Immunity 5:295-302.
18. Raychaudhuri, S. and Morrow, W.J. 1993. Can soluble antigens induce CD8+ cytotoxic T-cell responses? A paradox revisited. Immunol. Today 14:344-348.
19. Pamer, E. and Cresswell, P. 1998. Mechanisms of MHC class I-restricted antigen processing. Annu. Rev. Immunol. 16:323-358.
20. York, I.A. and Rock, K.L 1996. Antigen processing and presentation by the class I major histocompatibility complex. Annu. Rev, Immunol. 14:369-396.
21. Germain, R.N., Castellino, F., Man, R., Reis, E., Sousa, C., Romagnoli, P. et al. 1996. Processing and presentation of enocytically acquired protein antigens by MHC class II and class I molecules. Immunol. Rev. 151:5-30.
22. Chambers, C.A. and Allison, J.P. 1997. Co-stimulation in T-cell responses. Curr. Biol. 9:396-404.
23. Hart, D.N.J. 1997. Dendritic cells: Unique leukocyte populations which control the primary immune response. Blood 90:3245-3287.
24. Cella, M., Sallusto, F., and Lanzavecchia, A. 1997. Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol. 9:10-16.
25. Banchereau, J. and Steinman, R.M. 1998. Dendritic cells and the control of immunity. Nature 392:245-252.
26. Germain, R.N. 1997. T-cell signaling: the importance of receptor clustering. Curr. Biol. 7:R640-R644.
27. Watts, C. 1997. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu. Rev. Immunol. 15:821-850.
28. Moss, B. 1991. Vaccinia virus: a tool for research and vaccine development. Science 252:1662-1667.
29. Borysiewicz, L.K., Fiander, A., Nimako, M., Man, S., Wilkinson, G.W., Westmorland, D. et al. 1996. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer, Lancet 347:1523-1527.
30. Kwong, Y.T., Zaremba, S., Nieroda, C.A., Zhu, M.Z., Hamilton, J.M., and Schlom, J. 1995. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl. Cancer Inst. 87:982-990.
31. Chen, P.W., Wang, M., Bronte, V., Zhai, Y., Rosenberg, S.A., and Restifo, N.P. 1996. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J. Immunol. 156:224-231.
32. Rodrigues, E.G., Zavala, F., Eichinger, D., Wilson, J.M., and Tsuji, M. 1997. Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective Immunity against malaria. J. Immunol. 158:1268-1274.
33. Sadoff, J.C., Ballou, W.R., Baron, L.S., Majarian, W.R., Brey, R.N. et al. 1988. Oral salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science 240:336-338.
34. Schafer, R., Portnoy, DA, Brassell, S.A., and Paterson, Y. 1992. induction of a cellular immune response to a foreign antigen by a recombinant Listeria monocytogenes vaccine. J. Immunol. 149:53-59.
35. Aldovini, A. and Young, R.A. 1991. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature 351:479-482.
36. Stover, C.K., de la Cruz, V.F., Fuerst, TR., Burlein, J.E., Benson, L.A., Bennett, L.T. et al. 1991. New use of BCG for recombinant vaccines. Nature 351:456-460.
37. Guillaume, J.C., Saiag, P., Wechsler, J., Lescs, M.C., and Roujeau, J.C. 1991. Vaccinia from recombinant virus expressing HIV genes. Lancet 337:1034-1035.
38. Glorioso, J.C. 1996. Improving vectors. Gene Ther. 3:467-469.
39. Donnelly, J.J., Ulmer, J.B., Shiver, J.W., and Liu, M. DNA vaccines. 1997. Annu. Rev. Immunol. 15:617-618.
40. Robinson, H.L. and Torres, C.A. 1997. DNA vaccines. Semin Immunol. 5:271-283.
41. Johnston, S.A. and Barry, M.A. 1997. Genetic to genomic vaccination. Vaccine 15:808-809.
42. Boczkowski, D., Nair, S.K., Snyder, D., and Gilboa, E. 1996. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184:465-472.
43. Conry, R.M.J., Lo Buglio, A.F., Wright, M., Sumerel, L., Pike, M.J., Johanning, F. et al. 1995. Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res. 55:1397-1400.
44. Stauss, H.J., Davies, H., Sadovnikova, E., Chain, B., Horowitz, N., and Sinclair, C. 1992. Induction of cytotoxic T lymphocytes with peptides in vitro: Identification of candidate T-cell epitopes in human papilloma virus. Proc. Natl. Acad. Sci. USA 89:7871-7875.
45. Deres, K., Schild, H., Wiesmuller, K.H., Jung, G., and Rammensee, H.G. 1989. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine, Nature 342:561-564.
46. Rock, K.L., Fleischacker, C., and Gamble, S. 1993. Peptide-priming of cytolytic T cell immunity in vivo using beta 2-microglobulin as an adjuvant. J. Immunol. 150:1244-1252.
47. Young, J.W. and Inaba, K. 1996. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J. Exp. Med. 183:7-11.
48. Rock, K.L., Rothstein, L., and Benacerraf, B. 1992. Analysis of the association of peptides of optimal length to class I molecules on the surface of cells. Proc. Natl. Acad. Sci. USA 89:8918-8922.
49. Cheever, M.A., Disis, M.L., Bernhard, H., Gralow, J.R., Hand, S.L., Huseby, E.S. et al. 1995. Immunity to oncogenic proteins. Immunol. Rev. 145:33-59.
50. Men, Y., Gander, B., Merkte, H.P., and Corradin, G. 1996. Induction of sustained and elevated immune responses to weakly immunogenic synthetic malarial peptides by encapsulation in biodegradable polymer microspheres. Vaccine 14:1442-1450.
51. Disis, M.L. and Cheever, M.A. 1997. Her-2/neu protein: a target for antigen specific immunotherapy of human cancer. Adv. Cancer Res. 71:343-371.
52. Takahashi, H., Takeshita, T., Morein, B., Putney, S., Germain, R.N., and Berzofsky, J.A. 1990. Induction of CD8+ cytotoxic T cells by immunization with purified HIV1 envelope protein in ISCOMs. Nature 344:873-875.
53. Newman, M.J., Wu, J.Y., Gardner, B.H., Munroe, K.J., Leombruno, D., Recchia, J. et al. 1992. Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses. J. Immunol. 148:2357-2362.
54. Wu, J.Y., Gardner, B.H., Murphy, C.I., Seals, J.R., Kensll, C.R., Recchia, J. et al. 1992. Saponin adjuvant enhancement of antigen-specific immune responses to. an experimental HIV-1 vaccine. J. Immunol. 148:1519-1525.
55. Ulrich, J.T. and Myers, K.R. 1994. Monophosphoryl lipid A as an adjuvant: past experience and new directions, pp. 495-524, in Vaccine design., Powell M.F. and Newman M.J. (eds.), Plenum Press, NY.
56. Mitchell, M.S., Harel, and W., Groshen, S. 1992. Association of HLA phenotype with response to active specific immunotherapy of melanoma. J. Clin. Oncol. 10:1158-1164.
57. Allison, A.C. and Byars, N.E. 1991. Immunological adjuvants; desirable properties and side effects. Mol. Immunol. 3:279-284.
58. Raychaudhuri, S., Tonks, M., Carbone, F., Ryskamp, J., Morrow, W.J., and Hanna, N. 1992. Induction of antigen-specific class l-restricted cytotoxic T cells by soluble proteins in vivo, Proc. Natl. Acad. Sci. USA 89:8308-8312.
59. van Binnendijk, R.S., van Baalen, C.A., Poelen, M.C., de Vries, P., Boes. J., Cerundolo, V. et al. 1992. Measles virus transmembrane fusion protein synthesized de novo or presented in immunostimulating complexes is endogenously processed for HLA class I- and class II-restricted cytotoxic T cell recognition. J. Exp. Med. 176:119-128
60. Schirmbeck, R., Thoma, S., and Reimann, J. 1997. Processing of exogenous hepatitis B surface antigen particles for Ld-restricted epitope presentation depends on exogenous beta2-microglobulin. Eur. J. Immunol. 27:3471-3484.
61. Layton, G.T., Harris, S.J., Myhan, J., West, D., Gotch, F., Hill-Perkins, M. et al. 1996. Induction of single and dual cytotoxic T-lymphocyte responses to viral proteins in mice using recombinant hybrid Ty-virus-like particles. Immunology 87:171-178.
62. Harris, S.J., Woodrow, S.A., Gearing, A.J., Adams, S.E., Kingsman, A.J., and Layton, G.T. 1996. The effects of adjuvants on CTL induction by V3:Ty-vlrus-like particles (V3-VLPs) in mice. Vaccine 14:971-976.
63. Conner, M.E., Zarley, C.D., Hu, B., Parsons, S., Drabinski, D., Greiner, S. et al. 1996. Virus-like particles as a rotavirus subunit vaccine. J. Infect. Dis. 174:S88-S92.
64. Greenstone, H.L., Nieland, J.D., de Visser, K.E., De Bruijn, M.L., Kirnbauer, R., Roden, R.B. et al. 1998. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc. Natl. Acad. Sci. USA 95:1800-1805.
65. Sedlik, C., Saron, M., Sarraseca, J., Casal, I., and Leclerc, C. 1997. Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc. Natl. Acad. Sci. USA 94:7503-7508
66. Gilbert, S.C., Plebanski, M., Hartis, S.J., Allsopp, C.E., Thomas, R., Layton, G.T. et al. 1997. A protein particle vaccine containing multiple malaria epitopes. Nat. Biotechnol. 15:1280-1284.
67. Liu, T., Zhou, X., Orvell, C., Lederer, E., Ljunggren, H.G., and Jondal, M. 1995. Heat-inactivated sendai virus can enter multiple MHC class I processing pathways and generate cytotoxic T lymphocyte responses in vivo. J. Immunol. 154:3147-3155.
68. Speidel, K., Osen, W., Faath, S., Hilgert, I., Obst, R., Braspenning, J. et al. 1997. Priming of cytotoxic T lymphocytes by five heat-aggregated antigens In vivo: conditions, efficiency, and relation to antibody responses. Eur. J. Immunol. 27:2391-2399
69. Collins, D.S., Findlay, K., and Harding, C.V. 1992. Processing of exogenous liposome-encapsulated antigens in vivo generates class I MHC-restricted T cell responses. J. Immunol. 148:3336-3341.
70. Nair, S., Zhou, F., Reddy, R., Huang, L., and Rouse, B.T. 1992. Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro. J.Exp. Med. 175:609-612.
71. Suto, R. and Srivastava, P.K. 1995. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 289:1585-1588.
72. Suzue, K., Zhou, X., Eisen, H.N., and Young, R.A. 1997. Heat shock proteins as vehicles for antigen delivery Into the major histocompatibility complex class I presentation pathway. Proc. Natl. Acad. Sci. USA 94:13146-13151.
73. Rock, K.L., Gamble, S., and Rothstein, L. 1990. Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science 249:438-446.
74. Debrick, J.E., Campbell, P.A., and Staerz, U.D. 1991. Macrophages as accessory cells for class I MHC-restricted immune responses. J. Immunol. 147:2846-2851.
75. Denkers, E.Y., Gazzinelli, R.T., Hieny, S., Caspar, P., and Sher, A. 1993. Bone marrow macrophages process exogenous toxoplasma gondii polypeptides for recognition by parasite-specific cytolytic T lymphocytes. J. Immunol. 150:517-526.
76. Rock, K.L., Rothstein, L., Gamble, S., and Fleischacker, C. 1993. Characterization of antigen-presenting cells that present exogenous antigens in association with class I MHC molecules. J. Immunol. 150:438-446.
77. Kovacsovics-Bankowski, M., and Rock, K.L. 1995. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 267:243-246.
78. Harding, C.V. and Geuze, H.J. 1993. Antigen processing and intracellular traffic of antigens and MHC molecules. Curr. Opin. Cell Biol. 5:596-605.
79. Grant, E.R and Rock, K.L. 1992. MHC Class I-restricted presentation of exogenous antigen by thymic antigen-presenting cells in vitro and in vivo. J. Immunol. 148:13-18.
80. Norbury, C.C., Hewlett, L.J., Prescott, A.R., Shastri, N., and Watts, C. 1995. Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages. Immunity 3:783-791.
81. Reise-Sousa, C. and Germain, R.N. 1995. Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis. J. Exp. Med. 182:841-852.
82. Stahl, P.D. and Ezekowitz, R.A. 1998. The man nose receptor is a pattern recognition receptor involved In host defense. Curr. Opin. Immunol. 10:50-55.
83. Metalay, J.P. and Steinman, P.M. 1989. Control of the immune response at the level of antigen-presenting cells: a comparison of the function of dendritic cells and B lymphocytes. Adv. Immunol. 47:45-116.
84. Kovacsovics-Bankowski, M., Clark, K., Benacerraf, B., and Rock, K.L. 1993. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc. Natl. Acad, Sci. USA 90:4942-4946.
85. Harding, C.V. and Song, R. 1994. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecule. J. Immunol. 153:4925-4933.
86. Vidard, L., Kovacsovics-Bankowski, M., Kraeft, S.K., Chen, L.B., Benacerraf, B., and Rock, K.L. 1996. Analysis of MHC class II presentation of particulate antigens of B lymphocytes. J. Immunol. 156:2809-2818.
87. Jia-Yan, W, Gardner, B.H., Kushner, N.N., Pozzi, U.M., Kensil, C.R., Cloutier, P.A. et al. 1994. Accessory cell requirements for saponin adjuvant-induced class I MHC antigen-restricted cytotoxic T-lymphocytes. Cell Immunol. 154:393-406.
88. Wise, D.L., Fellman, T.D., Sanderson, J.E., Wentworth, R.L., and Gregoriadis, G. (eds.). 1997. Drug carriers in biology and medicine. Academic Press, New York.
89. Montera, T., Ogura, Y, Yoshimura, N., Honda, Y.,Wada, R., Hyon, S.H. et al. 1992. Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreretinopathy. Invest. Ophthalmol. Vis. Sci. 33:3125.
90. Rafferty, D.E., Elfaki, M.G., and Montgomery, P.C. 1996. Preparation and characterization of a biodegradable microparticle antigen/cytokine delivery system. Vaccine 14:532.
91. Marx, P.A., Compans, R.W., Gettie, A., Staas, J.K., Gilley, R.M., Mulligan, M.J. et al. 1993. Protection against vaginal SIV transmission with microencapsulated vaccine. Science 260:1323-1327.
92. Cahill, E.S., O'Hagan, D.T., IIlum, L., Barnard, A., Mills, K.H., and Redhead, K. 1995. Immune responses and protection against Bordetalla pertussis infection after intranasal immunization of mice with filamentous hasmagglutinin in solution or incorporated in biodegradable microparticles. Vaccine 13:455-462.
93. Vordermeier, H.M., Coombes, A.G., Jenkins, P., McGhee, J.P., O'Hagan, D.T. et al. 1995. Synthetic delivery system for tuberculosis vaccines: immunological evaluation of the M. tuberculoisis 38 kDa protein entrapped In biodegradable PLG microparticles. Vaccine 13:1576-1582.
94. Partidos, C.D., Vohra, P., Anagnostopoulou, C., Jones, D.H., Farrar, G.H., and Steward, M.W. 1996. Biodegradable microparticles as a delivery system for measles virus cytotoxic T cell epitopes. Mol. Immunol. 33:485-491.
95. Rock, K.L. and Clark, K. 1996. Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway. J. Immunol. 156:3721-3726.
96. Van den Eynde, B., Lethe, B., Van Pel, A., De Plaen, E., and Boon, T. 1991. The gene coding for a major tumor rejection antigen of tumor P815 Is Identical to the normal gene of syngeneic DBA/2 mice. J. Exp. Med. 173:1373-1384.
97. Li, Y., Hellstrom, K.E., Newby, S.A., and Chen, L. Costimulation by CD48 and B7- 1 induces immunity against poorly immunogenic tumors. 1996. J. Exp. Med. 183:639-644.
98. Fallarino, F., Uyttenhove, C., Boon, T., and Gajewski, T.F. 1996. Endogenous IL12 is necessary for rejection of P815 tumor variants in vivo. J. Immunol. 156:1095-1100,
99. Schmidt-Wolf, G. and Schmidt-Wolf, I.G.H. 1995. Cytokines and clinical gene therapy, Eur. J. Immunol. 25:1137-1140.
100. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K. et al. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA. 90:3539-3543
101. Pulendran, B., Lingappa, J., Kennedy, M.K., Smith, J., Tepee, M., Rudensky, A. et al. 1997. Developmental pathways of dendritic cells in vivo. Distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice. J. Immunol. 159:2222-2231.
102. Biron, C.A. and Gazzinelli, R.T. 1995. Effects of IL-12 on immune responses to microbial infections: a key mediator in regulating disease outcome. Curr. Opin. Immunol. 7:485-496.
103. O'Garra, A. 1998. Cytokines Induce the development of functionally heterogeneous T helper cell subsets. Immunity. 8:275-283.
104. Powrie, F. and Coffman, R.L. 1993. Cytokine regulation of T-cell function: potential for therapeutic intervention. Trends Pharmacol. Sci. 14:164-168.
105. Thompson, C.B. 1995. Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? Cell. 81:979-982.
106. O'Garra, A. 1997. Interleukin-12 and up: functions of T helper subsets resulting from differential cytokine production, Res. Immunol. 148:413-416.
107. Bronte, V., Tsung, K., Rao, J.B., Chen, P.W., Wang, M., Rosenberg, S.A. et al. 1995. II-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J. Immunol. 154:5282-5292.
108. Giovarelli, M., Musiani, P., Modesti, A., Dellabona, P., Casorati, G., Allione, A. et al. 1995. Local release of 11-10 by transfected mouse mammary adenocarclnoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J. Immunol. 155:3112-3123.
109. Mosmann, T.R. and Sad, S. 1996. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today. 17:138-146.
110. Mosmann, T.R., Li, L., Hengartner, H., Kagi, D., Fu, W., and Sad, S. 1997. Differentiation and functions of T cell subsets. Ciba. Found Symp. 204:148-154.
111. Probst, P., Skeiky,Y., Sleeves, M., Gervassi, A., Grabstein, K.H., and Reed, S.G. 1997. A leishmania protein that modulates interleukin (IL)-12, IL-10 and tumor necrosis factor-a production and expression of B7-1 in human monocyte-derived antigen-presenting cells. Eur. J. Immunol. 27:2634-2642.
112. Kwon, E.D., Hurwitz, A.A., Foster, B.A., Madias, C., Feldhaus, A.L., Greenberg, N.M. et al. 1997. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer Proc. Natl. Acad. Sci. USA 94:8099-8103.